Literature DB >> 11371406

Quality-adjusted survival in the first year after the acute respiratory distress syndrome.

D C Angus1, A A Musthafa, G Clermont, M F Griffin, W T Linde-Zwirble, T T Dremsizov, M R Pinsky.   

Abstract

There is little information on long-term outcome after acute respiratory distress syndrome (ARDS). We measured quality-adjusted survival in the first year after ARDS in a prospective cohort (n = 200). All patients met traditional criteria for ARDS. Patients with sepsis and acute nonpulmonary organ dysfunction at presentation were excluded. The cohort was healthy before onset of ARDS as evidenced by high functional status (mean Karnofsky Performance Status index: 82.2/100 where >/= 80 = able to perform normal activities independently) and minimal comorbid illness (mean Charlson-Deyo comorbidity score: 0.32/17 where 0 = absence of chronic illness). We determined quality-adjusted life-years (QALYs) using the Quality of Well-being (QWB) scale (0 to 1 scale where 1 = optimal well-being), measured at 6 and 12 mo. Survival was 69.5 +/- 5.0% at 1 month, fell to 55.7 +/- 3.7% at 6 mo, and did not change at 12 mo, yielding a survival of 59 life-years in the first year per 100 patients with ARDS. QWB was low at 6 and 12 mo (0.59 +/- 0.015 and 0.60 +/- 0.015), yielding a quality-adjusted survival of 36 QALYs per 100 patients (sensitivity range: 21 to 46 QALYs). We conclude that ARDS developing in previously healthy patients is associated with poor quality-adjusted survival. These data are important for cost-effectiveness analyses and long-term care.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371406     DOI: 10.1164/ajrccm.163.6.2005123

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  90 in total

Review 1.  The pulmonary physician in critical care: towards comprehensive critical care?

Authors:  M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Health status after critical illness: beyond descriptive studies.

Authors:  Gordon D Rubenfeld; J Randall Curtis
Journal:  Intensive Care Med       Date:  2003-10       Impact factor: 17.440

3.  Surviving intensive care: a report from the 2002 Brussels Roundtable.

Authors:  Derek C Angus; Jean Carlet
Journal:  Intensive Care Med       Date:  2003-01-21       Impact factor: 17.440

4.  Optimizing outcomes for older patients treated in the intensive care unit.

Authors:  E Wesley Ely
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

5.  Embracing physical and neuropsychological dysfunction in acute lung injury survivors: the time has come.

Authors:  Elie Azoulay; Marc Moss
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

6.  Predictors of health utility among 60-day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study.

Authors:  Kirsten L Johansen; Mark W Smith; Mark L Unruh; Andrew M Siroka; Theresa Z O'Connor; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

Review 7.  Studying outcomes of intensive care unit survivors: measuring exposures and outcomes.

Authors:  Dale M Needham; David W Dowdy; Pedro A Mendez-Tellez; Margaret S Herridge; Peter J Pronovost
Journal:  Intensive Care Med       Date:  2005-05-21       Impact factor: 17.440

8.  Organ dysfunction during sepsis.

Authors:  Suveer Singh; Timothy W Evans
Journal:  Intensive Care Med       Date:  2006-02-11       Impact factor: 17.440

9.  Mobile, awake and critically ill.

Authors:  Margaret S Herridge
Journal:  CMAJ       Date:  2008-03-11       Impact factor: 8.262

10.  Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study.

Authors:  James C Jackson; Pratik P Pandharipande; Timothy D Girard; Nathan E Brummel; Jennifer L Thompson; Christopher G Hughes; Brenda T Pun; Eduard E Vasilevskis; Alessandro Morandi; Ayumi K Shintani; Ramona O Hopkins; Gordon R Bernard; Robert S Dittus; E Wesley Ely
Journal:  Lancet Respir Med       Date:  2014-04-07       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.